539680 — GANGA PHARMACEUTICALS Income Statement
0.000.00%
- IN₹64.42m
- IN₹75.61m
- IN₹26.37m
Annual income statement for GANGA PHARMACEUTICALS, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | ARS | ARS | PRESS |
Standards: | IAS | IAS | — |
Status: | Final | Final | Final |
Revenue | |||
Total Revenue | 25.9 | 27.4 | 26.4 |
Cost of Revenue | |||
Gross Profit | 13.5 | 14.9 | 14.2 |
Selling / General / Administrative Expenses | |||
Depreciation and Amortization | |||
Other Operating Expenses | |||
Total Operating Expenses | 26.4 | 27.3 | 28 |
Operating Profit | -0.515 | 0.084 | -1.63 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | 0.531 | 0.633 | 0.947 |
Provision for Income Taxes | |||
Net Income After Taxes | 0.393 | 0.466 | 0.79 |
Net Income Before Extraordinary Items | |||
Net Income | 0.393 | 0.466 | 0.79 |
Adjustments to Net Income | |||
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | 0.393 | 0.466 | 0.79 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | 0.097 | 0.071 | 0.12 |